Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer

Weeden, Clare E.; Gayevskiy, Velimir; Marceaux, Claire; Batey, Daniel; Tan, Tania; Yokote, Kenta; Ribera, Nina Tubau; Clatch, Allison; Christo, Susan N; Teh, Charis E.; Mitchell, Andrew J.; Trussart, Marie; Rankin, Lucille C.; Obers, Andreas; McDonald, Jackson A.; Sutherland, Kate D.; Sharma, Varun; Starkey, Graham; D’Costa, Rohit; Antippa, Phillip; Leong, Tracy L.; Steinfort, Daniel; Irving, Louis; Swanton, Charles; Gordon, Claire L.; Mackay, Laura K.; Speed, Terence P.; Gray, Daniel H.D.; Asselin-Labat, Marie-Liesse

doi:10.1016/j.ccell.2023.03.019

Cited by 21 publications

(15 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most notably, memory CD4+ T cells were positively associated with more than a dozen bacteria in the low-risk group, compared with just two in the high-risk group. The role of memory T cells in LC has been extensively studied [ 37 , 38 ]. One study reported that when tissue-resident memory T cells are present in tumors, they act together to attack the cancer cells and protect the host [ 38 ].…”

Section: Resultsmentioning

confidence: 99%

Predictable regulation of survival by intratumoral microbe-immune crosstalk in patients with lung adenocarcinoma

Shi,

Chu,

Liu

et al. 2024

Microb Cell

View full text Add to dashboard Cite

Intratumoral microbiota can regulate the tumor immune microenvironment (TIME) and mediate tumor prognosis by promoting inflammatory response or inhibiting anti-tumor effects. Recent studies have elucidated the potential role of local tumor microbiota in the development and progression of lung adenocarcinoma (LUAD). However, whether intratumoral microbes are involved in the TIME that mediates the prognosis of LUAD remains unknown. Here, we obtained the matched tumor microbiome and host transcriptome and survival data of 478 patients with LUAD in The Cancer Genome Atlas (TCGA). Machine learning models based on immune cell marker genes can predict 1- to 5-year survival with relative accuracy. Patients were stratified into high- and low-survival-risk groups based on immune cell marker genes, with significant differences in intratumoral microbial communities. Specifically, patients in the high-risk group had significantly higher alpha diversity (p < 0.05) and were characterized by an enrichment of lung cancer-related genera such as Streptococcus. However, network analysis highlighted a more active pattern of dominant bacteria and immune cell crosstalk in TIME in the low-risk group compared to the high-risk group. Our study demonstrated that intratumoral microbiota-immune crosstalk was strongly associated with prognosis in LUAD patients, which would provide new targets for the development of precise therapeutic strategies.

show abstract

Section: Resultsmentioning

confidence: 99%

Predictable regulation of survival by intratumoral microbe-immune crosstalk in patients with lung adenocarcinoma

Shi,

Chu,

Liu

et al. 2024

Microb Cell

View full text Add to dashboard Cite

show abstract

“…Because of the tremendous success in the development of immunotherapy for cancer treatment, it is vital to investigate the link between NPCs and immune infiltration. Tumor immune T cells, PD1, and PDL1, all found in recent years, are key target cells or targets of cancer therapy with excellent effectiveness in certain cancer types. NPCs were, of course, significantly correlated with Th2, CD4_T, CD8_T, Th1, Th17, Tfh, and other immune T cells, and the Spearman correlation coefficients of NPCs with immune activators, immunosuppressants, MHC, and other molecules were all >2.5, indicating a strong correlation.…”

Section: Discussionmentioning

confidence: 99%

Focusing on the Abnormal Events of NPC1, NPC2, and NPC1L1 in Pan-Cancer and Further Constructing LUAD and KICH Prediction Models

Chen,

Zhang,

Sun

et al. 2023

J. Proteome Res.

View full text Add to dashboard Cite

Cancer’s high incidence and death rate jeopardize human health and life, and it has become a global public health issue. Some members of NPCs have been studied in a few cancers, but comprehensive and prognostic analysis is lacking in most cancers. In this study, we used the Cancer Genome Atlas (TCGA) data genomics and transcriptome technology to examine the differential expression and prognosis of NPCs in 33 cancer samples, as well as to investigate NPCs mutations and their effect on patient prognosis and to evaluate the methylation level of NPCs in cancer. The linked mechanisms and medication resistance were subsequently investigated in order to investigate prospective tumor therapy approaches. The relationships between NPCs and immune infiltration, immune cells, immunological regulatory substances, and immune pathways were also investigated. Finally, the LUAD and KICH prognostic prediction models were built using univariate and multivariate COX regression analysis. Additionally, the mRNA and protein levels of NPCs were also identified.

show abstract

“…CD8+ T cells accumulate in non-small cell lung cancer tumors and accumulate mainly in the tumor center ( 18 ). TRM can exert immune pressure on tumor cells at the early stage of tumor development, affecting tumor evolution and escape ( 19 ). The number and function of TRM are closely related to tumor prognosis and treatment response ( 20 ).…”

Section: Tissue-resident Immune Cells In Nsclcmentioning

confidence: 99%

“…The authors found that TRM cells were enriched in tumors with high PD-L1 expression and low tumor mutational burden, and that they recognized shared neoantigens that were present in most tumor cells ( 19 ). However, TRM also induced the emergence of subclones that escaped TRM recognition by losing or mutating the neoantigens ( 19 ). These subclones were resistant to PD-1 blockade and had poor prognosis.…”

Section: The Application Of Tissue-resident Immune Cells In Non-small...mentioning

confidence: 99%

Roles of tissue-resident immune cells in immunotherapy of non-small cell lung cancer

Tang,

Wang,

Tang

2023

Front. Immunol.

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) is the most common and lethal type of lung cancer, with limited treatment options and poor prognosis. Immunotherapy offers hope for improving the survival and quality of life of NSCLC patients, but its efficacy depends on the tumor immune microenvironment (TME). Tissue-resident immune cells are a subset of immune cells that reside in various tissues and organs, and play an important role in fighting tumors. In NSCLC, tissue-resident immune cells are heterogeneous in their distribution, phenotype, and function, and can either promote or inhibit tumor progression and response to immunotherapy. In this review, we summarize the current understanding on the characteristics, interactions, and roles of tissue-resident immune cells in NSCLC. We also discuss the potential applications of tissue-resident immune cells in NSCLC immunotherapy, including immune checkpoint inhibitors (ICIs), other immunomodulatory agents, and personalized cell-based therapies. We highlight the challenges and opportunities for developing targeted therapies for tissue-resident immune cells and optimizing existing immunotherapeutic approaches for NSCLC patients. We propose that tissue-resident immune cells are a key determinant of NSCLC outcome and immunotherapy response, and warrant further investigation in future research.

show abstract

Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer

Cited by 21 publications

References 75 publications

Predictable regulation of survival by intratumoral microbe-immune crosstalk in patients with lung adenocarcinoma

Predictable regulation of survival by intratumoral microbe-immune crosstalk in patients with lung adenocarcinoma

Focusing on the Abnormal Events of NPC1, NPC2, and NPC1L1 in Pan-Cancer and Further Constructing LUAD and KICH Prediction Models

Roles of tissue-resident immune cells in immunotherapy of non-small cell lung cancer

Contact Info

Product

Resources

About